NCT04156451

Effect of Fluid Deresuscitation With Central Venous Pressure Target 0-4 mmHg in Septic Shock Patients

Completed NA Last updated 2 May 2025

What this trial tests

NA trial testing Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg in Septic Shock in 44 participants. Completed in 30 November 2020.

Timeline

14 November 2019

Primary endpoint
30 September 2020

30 November 2020

Quick facts

Lead sponsor	Indonesia University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	44
Start date	14 November 2019
Primary completion	30 September 2020
Estimated completion	30 November 2020
Sites	1 location across Indonesia

Drugs / interventions tested

• Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg
• Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg

Conditions studied

• Septic Shock — all drugs for Septic Shock →

Sponsor

Indonesia University

Who can join

Adults 18 to 80, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A scientific research to prove the safety and effectiveness of TVS 0 - 4 mmHg as a target of resuscitation using furosemide, to improve Perfused Vessel Density (PVD) \> 25 mm / mm2, AKI stage (based on KDIGO criteria), CI \> 2.5 cc / min / m2 , prevent the incidence of intubation, reduce the duration of ventilator use \<120 hours and reduce the length of ICU stay in patients with septic shock after resuscitation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.